BioMotiv

BioMotiv is a mission-driven accelerator associated with The Harrington Project for Discovery & Development, a $250 million initiative centered at University Hospitals in Cleveland, Ohio. The focus is to accelerate breakthrough discoveries from research institutions into therapeutics for patients through an innovative model that efficiently aligns capital and collaborations. The company leverages an experienced team and advisory board to select, fund, and actively manage and advance a portfolio of programs. Products are advanced to clinical proof-of-concept and then partnered.

BioMotiv's investment strategy encompasses a broad spectrum of therapeutic areas, including immunology, oncology, cardiology, and infectious diseases. The company engages in various stages of investment, from seed funding to late-stage development, aiming to bridge the gap between early-stage research and commercial success. By collaborating with academic institutions, disease foundations, and industry partners, BioMotiv seeks to expedite the development of novel medical treatments.

The company's track record includes strategic partnerships with major pharmaceutical companies, such as Takeda Pharmaceutical Company, which invested $25 million over five years to support programs in immunology and cardiometabolic diseases. This partnership exemplifies BioMotiv's commitment to advancing medical innovations through collaborative efforts, ensuring that promising discoveries reach the patients who need them most.